Key Insights

Highlights

Success Rate

86% trial completion

Published Results

1289 trials with published results (15%)

Research Maturity

4365 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.9%

700 terminated out of 8817 trials

Success Rate

86.2%

-0.4% vs benchmark

Late-Stage Pipeline

11%

949 trials in Phase 3/4

Results Transparency

30%

1289 of 4365 completed with results

Key Signals

1289 with results86% success700 terminated

Data Visualizations

Phase Distribution

6,679Total
Not Applicable (2777)
Early P 1 (127)
P 1 (1037)
P 2 (1789)
P 3 (774)
P 4 (175)

Trial Status

Completed4,365
Recruiting1,229
Unknown1,216
Terminated700
Active Not Recruiting552
Not Yet Recruiting398

Trial Success Rate

86.2%

Benchmark: 86.5%

Based on 4365 completed trials

Clinical Trials (8817)

Showing 20 of 20 trials
NCT05896189Not ApplicableActive Not RecruitingPrimary

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

NCT07737132Not ApplicableNot Yet RecruitingPrimary

Comparison of Postoperative Analgesic Efficacy of Two Different Blocks in Modified Radical Mastectomy Surgery

NCT06068257Completed

Tumor-Derived FGF19

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT07619534Not Yet RecruitingPrimary

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

NCT07686250Phase 2RecruitingPrimary

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

NCT07040514Not ApplicableCompletedPrimary

24GUT540 : Meeting of Breast Cancer Patients and Pathologists

NCT06959537Phase 1RecruitingPrimary

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

NCT07737951Not ApplicableNot Yet Recruiting

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

NCT05754658CompletedPrimary

African Cancer Genome: GMD

NCT07590505Phase 3CompletedPrimary

Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast Cancer

NCT04889924Not ApplicableRecruitingPrimary

ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

NCT07734389Not ApplicableRecruitingPrimary

Genetic Assessment of Breast Cancer Risk in Women in the DORA Programme

NCT07732686Not Yet Recruiting

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT07732491Phase 2RecruitingPrimary

Culmerciclib in HR+/HER2+ Advanced Breast Cancer

NCT06075758CompletedPrimary

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

NCT01441089Recruiting

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

NCT07732101Not ApplicableNot Yet Recruiting

Exercise Intervention for Breast Cancer Patients With Sarcopenia

NCT06121453Not ApplicableRecruitingPrimary

Adherence Intervention in Patients With Metastatic Breast Cancer

NCT07731477Not ApplicableRecruitingPrimary

The Effect of a Virtual Reality-Based Mindfulness Intervention on Anxiety, Comfort, Sleep, and Fatigue in Breast Cancer Patients Undergoing Chemotherapy

Scroll to load more

Research Network

Activity Timeline